AstraZeneca has secured Food and Drug Administration priority review for its new dosing regimen of tremelimumab/Imfinzi to treat liver cancer. The FDA is expected to make a decision later this year. (Seeking Alpha

The World Health Organization said at least one child has died in connection with a mysterious liver disease outbreak across a dozen countries. The organization has received reports of nearly 170 cases of “acute hepatitis of unknown origin.” (Associated Press)

Quarterly earnings reports from Merck, Eli Lilly and Bristol Myers Squibb this week could prove Big Pharma’s defensive value. While the broader S&P 500 is down more than 10% this year, the S&P 500 Pharmaceuticals index is down just over 1% and was in the black a few weeks ago. (Barron’s)

Nasal sprays are positioned to be the next weapon against COVID. Advocates of this approach argue that it encourages the body to develop infection-blocking defenses in the sinuses and throat, which allow it to start fighting COVID much faster than an injected vaccine can. (Bloomberg)

Embattled biotech CytRx hired serial entrepreneur and medical venture capitalist Stephen Snowdy as its CEO. The company also instituted a number of cost-saving initiatives. (Los Angeles Business Journal)